NCT03556631View on ClinicalTrials.gov

Effect of Live Combined Bifidobacterium and Lactobacillus on Glycemic Control and Other Outcomes in Type 1 Diabetes

PHASE4CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 1, 2020

Primary Completion Date

September 30, 2021

Study Completion Date

October 30, 2021

Conditions
Type 1 Diabetes MellitusProbiotics
Interventions
DRUG

live combined Bifidobacterium and Lactobacillus Tablets

take the live combined Bifidobacterium and Lactobacillus Tablets 4# or placebo twice a day

Trial Locations (1)

518020

Shenzhen People' S Hospital, Shenzhen

All Listed Sponsors
lead

Shenzhen People's Hospital

OTHER

NCT03556631 - Effect of Live Combined Bifidobacterium and Lactobacillus on Glycemic Control and Other Outcomes in Type 1 Diabetes | Biotech Hunter | Biotech Hunter